{"id":7662,"date":"2018-04-05T00:00:00","date_gmt":"2018-04-04T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2018\/04\/05\/nova-diana-terapeutica-potencial-contra-el-sarcoma-dewing\/"},"modified":"2020-05-13T19:46:26","modified_gmt":"2020-05-13T17:46:26","slug":"nova-diana-terapeutica-potencial-contra-el-sarcoma-dewing","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2018\/04\/nova-diana-terapeutica-potencial-contra-el-sarcoma-dewing\/","title":{"rendered":"Nova diana terap\u00e8utica potencial contra el sarcoma d\u2019Ewing"},"content":{"rendered":"<table cellpadding=\"3\" height=\"100%\" width=\"100%\">\n<tbody>\n<tr>\n<td>\n<p>Investigadors del grup de recerca en sarcomes Oncobell de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), liderat pel Dr. \u00d2scar Mart\u00ednez-Tirado, han identificat una\u00a0<strong>potencial nova diana terap\u00e8utica per al sarcoma d\u2019Ewing<\/strong>, el segon c\u00e0ncer d\u2019os m\u00e9s freq\u00fcent en nens i adolescents, caracteritzat per la seva agressivitat i tend\u00e8ncia a metastatitzar. La recerca, publicada a\u00a0<em>International Journal of Cancer<\/em>, ha estat\u00a0<strong>finan\u00e7ada pr\u00e0cticament en la seva totalitat per la Fundaci\u00f3 Alba P\u00e9rez<\/strong>, una entitat sense \u00e0nim de lucre dedicada en exclusiva a aquesta malaltia.\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Des de fa anys, la principal l\u00ednia de recerca del grup en sarcoma d\u2019Ewing se centrava la prote\u00efna caveolina 1 (CAV1), que s\u2019havia pogut relacionar amb l\u2019aparici\u00f3 de resist\u00e8ncia al tractament i met\u00e0stasi, entre d\u2019altres. No obstant, la localitzaci\u00f3 d\u2019aquesta prote\u00efna en la c\u00e8l\u00b7lula dificulta el seu \u00fas com a diana terap\u00e8utica.\u00a0<strong>\u201c\u00c9s per aix\u00f2 que cerc\u00e0vem un cofactor de CAV1 amb un paper igual de rellevant per\u00f2 m\u00e9s accessible\u201d,\u00a0<\/strong>explica el Dr. Mart\u00ednez-Tirado, \u201c<strong>i el receptor de membrana EphA2, ja descrit en anteriors treballs, compleix aquestes condicions<\/strong>\u201d.<\/p>\n<p>\u00a0<\/p>\n<p>En el seu darrer treball, els investigadors no nom\u00e9s demostren la connexi\u00f3 entre el receptor EphA2 i la caveolina 1, sin\u00f3 que tamb\u00e9 estableixen una correlaci\u00f3 entre la fosforil\u00b7laci\u00f3 d\u2019EphA2 i l\u2019agressivitat dels tumors en sarcoma d\u2019Ewing.\u00a0<strong>\u201cEn estudis\u00a0<em>in vitro<\/em>i\u00a0<em>in vivo<\/em>, vam observar que aquest receptor de membrana \u00e9s una pe\u00e7a fonamental de cara a la migraci\u00f3 de les c\u00e8l\u00b7lules tumorals\u201d<\/strong>.<\/p>\n<p>\u00a0<\/p>\n<p>Pel que fa als estudis\u00a0<em>in vivo<\/em>, l\u2019equip de recerca va fer servir dos models. El model artificial de met\u00e0stasi, m\u00e9s experimental, permet valorar la capacitat de les c\u00e8l\u00b7lules per adherir-se a l\u2019epitel\u00b7li pulmonar en condicions adverses. D\u2019altra banda,\u00a0<strong>el nou model ortot\u00f2pic desenvolupat pel mateix grup fa uns mesos, permet induir una met\u00e0stasi espont\u00e0nia,<\/strong>\u00a0de forma molt m\u00e9s similar a la cl\u00ednica.<\/p>\n<p>\u00a0<\/p>\n<p><strong>\u201cAl laboratori, hem demostrat que la falta de receptor EphA2 disminueix molt\u00a0 signiticativament la incid\u00e8ncia i el n\u00famero de met\u00e0stasis\u201d<\/strong>, comenta el Dr. Mart\u00ednez-Tirado, \u201ci gr\u00e0cies a la col\u00b7laboraci\u00f3 amb l\u2019Hospital Virgen del Roc\u00edo, tamb\u00e9 hem constatat que el 90% dels pacients de sarcoma d\u2019Ewing expressen aquest receptor (mimetitzant la caveolina 1), fet fonamental de cara a catalogar-lo com a diana terap\u00e8utica. Paral\u00b7lelament, el treball amb mostres de pacients tamb\u00e9 ens ha perm\u00e8s correlacionar l\u2019activitat independent del lligand del receptor EphA2, associada a la seva fosforil\u00b7laci\u00f3, amb una pitjor superviv\u00e8ncia\u201d.<\/p>\n<p>\u00a0<\/p>\n<p>Gr\u00e0cies al suport econ\u00f2mic continuat de la Fundaci\u00f3 Alba P\u00e9rez, els investigadors de l\u2019IDIBELL podran seguir treballant en el desenvolupament de tractaments capa\u00e7os de bloquejar l\u2019activitat d\u2019aquest receptor. \u201c<strong>Mitjan\u00e7ant t\u00e8cniques de nanoenginyeria de f\u00e0rmacs, esperem desenvolupar una mol\u00e8cula amb doble efecte, capa\u00e7 tant de bloquejar EphA2 en les c\u00e8l\u00b7lules tumorals com d\u2019administrar altres ter\u00e0pies de forma dirigida<\/strong>\u201d, conclou l\u2019investigador de l\u2019IDIBELL.<\/p>\n<\/td>\n<\/tr>\n<tr><\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Investigadors del grup de recerca en sarcomes Oncobell de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), liderat pel Dr. \u00d2scar Mart\u00ednez-Tirado, han identificat una\u00a0potencial nova diana terap\u00e8utica per al sarcoma d\u2019Ewing, el segon c\u00e0ncer d\u2019os m\u00e9s freq\u00fcent en nens i adolescents, caracteritzat per la seva agressivitat i tend\u00e8ncia a metastatitzar. La recerca, publicada a\u00a0International Journal of [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":10590,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,398],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-12 21:20:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7662"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7662"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10590"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}